PMID- 31616710
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 7
IP  - 18
DP  - 2019 Sep 26
TI  - Guillain-Barre syndrome in a patient with multiple myeloma after bortezomib 
      therapy: A case report.
PG  - 2905-2909
LID - 10.12998/wjcc.v7.i18.2905 [doi]
AB  - BACKGROUND: Bortezomib is a first-line drug approved for patients with multiple 
      myeloma (MM) and has significantly increased their overall survival. However, 
      bortezomib-induced peripheral neuropathy (PN) remains a significant side effect 
      that has led to its discontinuation in some patients. Guillain-Barre syndrome 
      (GBS) is recognized as an immune-mediated PN characterized by the involvement of 
      multiple nerve roots and peripheral nerves and albuminocytologic dissociation in 
      cerebrospinal fluid (CSF) tests. Intravenous immunoglobulin (IVIG) and 
      plasmapheresis are effective. CASE SUMMARY: A 45-year-old man diagnosed with 
      stage III MM (lambda type) was treated with bortezomib and dexamethasone. Fourteen 
      days after the second course, he complained of intense burning sensation in the 
      lower limbs and hands, loss of tactile sensation, and pain in the distal area of 
      both thighs and in the distal part of both wrist joints. Neurological examination 
      revealed absence of knee and ankle reflexes. CSF examination revealed 
      albuminocytologic dissociation. Nerve conduction studies indicated sensory nerve 
      action potential amplitudes, conduction velocity decrease, and F wave latency 
      prolongation. He was diagnosed as MM complicated with GBS. Subsequently, he was 
      treated with high-dose IVIG (400 mg/kg/d for five days). His symptoms fully 
      resolved without relapse at the 6-month follow-up. CONCLUSION: Our case 
      highlights the differential diagnosis and management of complications after 
      bortezomib treatment in MM.
CI  - (c)The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Xu, Yu-Ling
AU  - Xu YL
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Zhao, Wei-Hua
AU  - Zhao WH
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Tang, Zhong-Yuan
AU  - Tang ZY
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Li, Zhong-Qing
AU  - Li ZQ
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Long, Yuan
AU  - Long Y
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Cheng, Peng
AU  - Cheng P
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Luo, Jun
AU  - Luo J
AD  - Department of Hematology, the First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China. 
      luojungz@medmail.com.cn.
LA  - eng
PT  - Case Reports
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC6789385
OTO - NOTNLM
OT  - Bortezomib
OT  - Case report
OT  - Guillain-Barre syndrome
OT  - Multiple myeloma
COIS- Conflict-of-interest statement: The authors declare that they have no competing 
      interests.
EDAT- 2019/10/17 06:00
MHDA- 2019/10/17 06:01
PMCR- 2019/09/26
CRDT- 2019/10/17 06:00
PHST- 2019/04/11 00:00 [received]
PHST- 2019/08/13 00:00 [revised]
PHST- 2019/08/26 00:00 [accepted]
PHST- 2019/10/17 06:00 [entrez]
PHST- 2019/10/17 06:00 [pubmed]
PHST- 2019/10/17 06:01 [medline]
PHST- 2019/09/26 00:00 [pmc-release]
AID - 10.12998/wjcc.v7.i18.2905 [doi]
PST - ppublish
SO  - World J Clin Cases. 2019 Sep 26;7(18):2905-2909. doi: 10.12998/wjcc.v7.i18.2905.